Efficacy and safety of levetiracetam (up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: A multicenter, randomized, double-blind, placebo-controlled study

Epilepsia

Volumn 47, Issue 1, 2006, Pages 72-81

  Tsai, Jing Jane ^a   Yen, Der Jen ^b   Hsih, Mo Song ^c   Chen, Shung Sheng ^c   Hiersemenzel, Reinhard ^d   Edrich, Pascal ^e   Lai, Chi Wan ^e,f  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d UCB PHARMA   (Belgium)

^e TZU CHI UNIVERSITY   (Taiwan)

^f KOO FOUNDATION SUN YAT SEN CANCER CENTER   (Taiwan)

Author keywords

Adjunctive therapy; Adults; Epilepsy; Levetiracetam; Partial seizures; Refractory seizures; Taiwanese patients

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; ETIRACETAM; PLACEBO;

ADOLESCENT; ADULT; AGITATION; ARTICLE; CLINICAL TRIAL; COMMON COLD; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DIPLOPIA; DISSOCIATIVE DISORDER; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FALLING; FEMALE; FEVER; FOCAL EPILEPSY; GRAND MAL SEIZURE; HEADACHE; HEART DISEASE; HEMATOMA; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MOOD DISORDER; MULTICENTER STUDY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK ASSESSMENT; SIDE EFFECT; SOMNOLENCE;

ADOLESCENT; ADULT; ANTICONVULSANTS; ASIAN CONTINENTAL ANCESTRY GROUP; CROSS-OVER STUDIES; DIZZINESS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; EPILEPSIES, PARTIAL; FEMALE; HEADACHE; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; PIRACETAM; PLACEBOS; SLEEP DISORDERS; TAIWAN; TREATMENT OUTCOME;

EID: 33645019934     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2006.00372.x     Document Type: Article

References (21)

1. Shorvon SD van Rijckevorsel K A new antiepileptic drug J Neurol Neurosurg Psychiatry 2002 72 426 428
2. French J Edrich P Cramer JA A systematic review of the safety profile of levetiracetam: a new antiepileptic drug Epilepsy Res 2001 47 77 90
3. Marson AG Hutton JL Leach JP et al Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review Epilepsy Res 2001 46 259 270
4. Cereghino JJ Biton V Abou-Khalil B et al and the United States Levetiracetam Study Group Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial Neurology 2000 55 236 242
5. Shorvon SD Löwenthal A Janz D et al and the European Levetiracetam Study Group Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures Epilepsia 2000 41 1179 1186
6. Ben-Menachem E Falter U and the European Levetiracetam Study Group Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy Epilepsia 2000 41 1276 1283
7. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: ethnic factors in the acceptability of foreign clinical data E5 Recommended for Adoption at Step 4 of the ICH Process on 5 February 1998 by the ICH Steering Committee (including Post Step 4 corrections agreed by the Steering Committee on 11 March 1998) Accessible at
8. Announcement of Bridging Study, Department of Health, Taiwan Accessible at
9. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6 Recommended for Adoption at Step 4 of the ICH Process on 1 May 1996 by the ICH Steering Committee (including Post Step 4 corrections agreed by the Steering Committee on 10 June 1996) Accessible at
10. Altman DG Schulz KF Moher D et al for the CONSORT Group The Revised CONSORT Statement for Reporting Randomized Trials: explanation and elaboration Ann Intern Med 2001 134 663 694
11. French J Arrigo C Rapid onset of action of levetiracetam in refractory epilepsy patients Epilepsia 2005 46 324 326
12. French J di Nicola S Arrigo C Fast and sustained efficacy of levetiracetam during titration and the first 3 months of treatment in refractory epilepsy Epilepsia 2005 in press
13. Somerville R Aggravation of partial seizures by antiepileptic drugs: is there evidence from clinical trials? Neurology 2002 59 79 83
14. Ben-Menachem E Edrich P van Vleymen B et al Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy Epilepsy Res 2003 53 57 64
15. Nicolas J-M Collart P Gerin B et al In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent Drug Metab Dispos 1999 27 250 254
16. Weinshilboum R Inheritance and drug response N Engl J Med 2003 348 529 537
17. Goldstein JA Clinical relevance of genetic polymorphisms in the human CYP2C subfamily Br J Clin Pharmacol 2001 52 349 355
18. Spear BB Pharmacogenetics and antiepileptic drugs Epilepsia 2001 42 suppl 5 31 34
19. Marson AG Kadir ZA Hutton JL et al The new antiepileptic drugs: a systematic review of their efficacy and tolerability Epilepsia 1997 38 233 234
20. Cramer JA Ben Menachem E French J Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation Epilepsy Res 2001 47 17 25
21. Eng CO Arrigo C van Rijckevorsel K et al Meta-analysis and indirect comparison of levetiracetam with second-generation antiepileptic drugs in partial epilepsy Clin Neuropharmacol 2005 28 72 78